Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression

被引:78
作者
Kyle, Robert A. [1 ]
Rajkumar, S. Vincent [1 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN USA
关键词
monoclonal gammopathy of undetermined significance; multiple myeloma; macroglobulinaemia; smouldering multiple myeloma;
D O I
10.1111/j.1365-2141.2007.06873.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Monoclonal gammopathy of undetermined significance (MGUS) is characterized by a serum monoclonal protein < 30 g/l, < 10% plasma cells in the bone marrow, and absence of end-organ damage (CRAB-hypercalcaemia, renal insufficiency, anaemia, or bone lesions). MGUS is present in 3% of persons > 50 years and in 5% > 70 years of age. The risk of progression to multiple myeloma (MM) or a related disorder is 1% per year. Patients with risk factors consisting of an abnormal serum free light chain ratio, non-immunoglobulin G (IgG) MGUS, and an elevated serum M protein >= 15 g/l had a risk of progression at 20 years of 58%, compared with 37% with two risk factors present, 21% with one risk factor present, and 5% when none of the risk factors were present. Smouldering (asymptomatic) multiple myeloma is characterized by having a serum IgG or IgA monoclonal protein of 30 g/l or higher and/or 10% or more plasma cells in the bone marrow but no evidence of end-organ damage. The cumulative probability of progression to active MM or amyloidosis was 51% at 5 years, 66% at 10 years and 73% at 15 years; the median time to progression was 4.8 years.
引用
收藏
页码:730 / 743
页数:14
相关论文
共 86 条
  • [1] ALEXANIAN R, 1975, ARCH INTERN MED, V135, P62, DOI 10.1001/archinte.135.1.62
  • [2] Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism - A prospective study
    Arnulf, B
    Bengoufa, D
    Sarfati, E
    Toubert, ME
    Meignin, V
    Brouet, JC
    Fermand, JP
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (04) : 464 - 467
  • [3] Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement
    Asatiani, E
    Cohen, P
    Ozdemirli, M
    Kessler, CM
    Mavromatis, B
    Cheson, BD
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2004, 77 (02) : 144 - 146
  • [4] Avet-Loiseau H, 1999, CANCER RES, V59, P4546
  • [5] Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma
    Avet-Loiseau, H
    Li, JY
    Morineau, N
    Facon, T
    Brigaudeau, C
    Harousseau, JL
    Grosbois, B
    Bataille, R
    [J]. BLOOD, 1999, 94 (08) : 2583 - 2589
  • [6] Avet-Loiseau H, 1998, CANCER RES, V58, P5640
  • [7] AXELSSON U, 1966, ACTA MED SCAND, V179, P235
  • [8] Badley A D, 1996, Liver Transpl Surg, V2, P375, DOI 10.1002/lt.500020508
  • [9] Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: Proposal for a common prognostic scoring system
    Baldini, L
    Goldaniga, M
    Guffanti, A
    Broglia, C
    Cortelazzo, S
    Rossi, A
    Morra, E
    Colombi, M
    Callea, V
    Pogliani, E
    Ilariucci, F
    Luminari, S
    Morel, P
    Merlini, G
    Gobbi, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) : 4662 - 4668
  • [10] Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy
    Baldini, L
    Guffanti, A
    Cesana, BM
    Colombi, M
    Chiorboli, O
    Damilano, I
    Maiolo, AT
    [J]. BLOOD, 1996, 87 (03) : 912 - 918